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ABSTRACT
Reduced dietary protein intake and intermittent fasting (IF) are both linked 
to healthy longevity in rodents, and are effective in inhibiting cancer growth. 
The molecular mechanisms underlying the beneficial effects of chronic protein 
restriction (PR) and IF are unclear, but may be mediated in part by a down-
regulation of the IGF/mTOR pathway. In this study we compared the effects of 
PR and IF on tumor growth in a xenograft mouse model of breast cancer. We also 
investigated the effects of PR and IF on the mechanistic Target Of Rapamycin 
(mTOR) pathway, inhibition of which extends lifespan in model organisms including 
mice. The mTOR protein kinase is found in two distinct complexes, of which mTOR 
complex 1 (mTORC1) is responsive to acute treatment with amino acids in cell 
culture and in vivo. We found that both PR and IF inhibit tumor growth and mTORC1 
phosphorylation in tumor xenografts. In somatic tissues, we found that PR, but 
not IF, selectively inhibits the activity of the amino acid sensitive mTORC1, while 
the activity of the second mTOR complex, mTORC2, was relatively unaffected by 
PR. In contrast, IF resulted in increased S6 phosphorylation in multiple metabolic 
tissues. Our work represents the first finding that PR may reduce mTORC1 activity 
in tumors and multiple somatic tissues, and suggest that PR may represent a highly 




Chronic restriction of dietary protein intake and 
intermittent fasting are both strongly associated with 
health and longevity in rodents [1–4]. Epidemiological 
data suggest high protein intake is associated with a 75% 
increase in overall mortality in humans, as well as a 4-fold 
increase in cancer death [1, 5]. Protein restriction (PR) 
and intermittent fasting (IF) regimens also show beneficial 
effects on rodent models of age-related diseases, including 
cancer and Alzheimer’s disease [6–8]. However, the 
molecular mechanisms underlying the beneficial effect of 
PR and IF diets on metabolic health and longevity have 
not been clearly established, although PR and IF diets 
significantly reduce circulating levels of IGF-1 (Insulin-
like growth factor 1), a potent activator of the mTOR 
(mechanistic Target Of Rapamycin) signaling pathway 
[9, 10].
Inhibition of the insulin/IGF-1/PI3K/mTOR 
signaling pathway either genetically or by treatment 
with the FDA-approved pharmaceutical rapamycin 
promotes longevity and inhibits tumor growth in model 
organisms [7, 11–14]. Unfortunately, the potentially 
serious side effects of rapamycin and rapamycin analogs 
in humans may preclude the use of these compounds 
to prevent or delay age-related diseases [15, 16]. The 
mTOR protein kinase is found in two complexes, mTOR 
complex 1 (mTORC1) and mTORC2, each with distinct 
substrates; genetic studies have demonstrated that 
inhibition of mTORC1 signaling is sufficient to extend 
lifespan, while inhibition of mTORC2 reduces insulin 
sensitivity and decreases male lifespan [17]. We and 
others have demonstrated that chronic treatment of mice 
with rapamycin results in the disruption of both mTOR 
complexes [18, 19]. Disruption of mTORC2 contributes 
to the negative metabolic and immunological side-effects 
of rapamycin, and we have proposed that specifically 
inhibiting mTORC1 would promote longevity and 
prevent age-associated diseases (e.g. cancer) with many 
fewer side effects than rapamycin, which inhibits both 
complexes [16].
In this study we compared the effects of chronic 
or intermittent reduction of protein intake on tumor 
growth in a xenograft mouse model of breast cancer. 
As amino acid levels in serum and tissue are regulated 
by dietary protein intake [20], and mTORC1 is acutely 
sensitive to amino acids, which activate mTORC1 
by promoting its localization to the lysosome and its 
interaction with Rheb, we also examined mTORC1 
and mTORC2 signaling not only in the xenograft 
tumors but also in several key metabolic tissues (liver, 
skeletal muscle, heart muscle and adipose tissue) of 
mice fed either a 21% and 7% protein diet ad libitum, or 
maintained on an IF regimen utilizing either a 21% or 
7% protein diet.
RESULTS
Protein restriction and intermittent fasting 
inhibit tumor growth in a human breast 
cancer model
To test the hypothesis that chronic dietary PR was 
more effective than intermittent fasting (IF) in inhibiting 
tumor growth in an animal model of human breast cancer, 
we acclimatized 4–6 week old female NOD-SCID mice 
to either a 21% or 7% (PR) protein diet, fed ad libitum 
or intermittently (IF) for 4 weeks, prior to subcutaneous 
implantation of WHIM16 ER+/PR-/HER2- tumor cells. 
Mice fed a PR diet either ad libitum or intermittently were 
approximately 10–15% lighter than mice fed a control diet 
by the latter half of the study, while mice fed a 21% diet 
intermittently were the same weight as ad libitum fed mice 
(Fig. 1A). As we have previously shown [7], the growth 
of WHIM16 ER+/PR-/HER2- xenografts is significantly 
reduced in mice fed a 7% protein diet ad libitum compared 
to a 21% protein control diet (Fig. 1B). Interestingly, we 
find that IF has similar effects, independent of dietary 
protein intake, in reducing tumor growth. The tumor 
growth rate in mice fed either diet intermittently (every 
other day) was significantly smaller than that in mice 
on an ad libitum 21% protein diet (Fig. 1C). The tumor 
volume of IF mice was significantly lower than of mice 
fed either a 21% or a 7% protein diet ad libitum during the 
second part of the study (Fig. 1B).
Protein restriction attenuates mTOR activity in 
human breast cancer xenografts
The mTOR signaling pathway is a critical regulator 
of growth and cellular proliferation, and mutations 
that activate mTORC1 are linked to cancer [21–23]. 
mTORC1 activity is highly responsive to amino 
acids, which are significantly reduced in mice on a PR 
diet [24, 25], and mTORC1 is significantly reduced on 
a protein-free diet [20]. We were therefore interested 
in determining whether or not a 2/3rds reduction in 
protein intake down-regulates the mTORC1 signaling 
pathway in a mouse model of human breast cancer, 
and whether this effect was stronger than intermittent 
fasting, in which proteins are reduced intermittently. To 
test this hypothesis, we assessed the phosphorylation of 
S6 S240/S244, a substrate of S6K1 and a readout for 
mTORC1 activity. We also assessed the phosphorylation 
of AKT S473, a substrate of the amino acid insensitive 
mTORC2.
As shown in Fig. 2, tumors from mice fed a PR 
diet ad libitum or mice subject to intermittent fasting 
of a 21% protein diet had an over 30% decrease in 
phosphorylated S6, indicating decreased mTORC1 
activity (Fig. 2A, 2B). Interestingly, while mice 
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intermittently fasted with a PR diet had normal levels 
of S6 phosphorylation (Fig. 2B), the expression of S6 
itself was significantly reduced (Fig. 2C). Biogenesis of 
ribosomal proteins like S6 is itself mediated 
by  mTORC1 [26, 27], suggesting that mTORC1 
activity was decreased in these tumors as well. We 
determined that the abundance of phosphorylated S6 
in the tumors of mice intermittently fasted with a PR 
diet relative to control, ad libitum mice was decreased 
by 44% (p = 0.002). In agreement with our hypothesis 
that reduced protein intake would specifically reduce 
mTORC1 activity, phosphorylation of AKT S473 
was not affected by PR; however, intermittent fasting 
significantly decreased AKT phosphorylation (Fig. 2B).
A low protein diet inhibits mTORC1 but not 
mTORC2 signaling in somatic tissues
We collected liver, skeletal muscle, heart, and 
adipose tissues at the end of the tumor xenograft study, 
and examined tissue lysates by Western blotting to test 
the systemic effects of protein restriction and intermittent 
fasting on other key metabolic tissues. We observed a 
dramatic effect of a PR diet on mTORC1 signaling in 
somatic tissues, including a greater than 60% decrease 
in S6 phosphorylation in liver (p = 0.007) and skeletal 
muscle (p = 0.0067), and a 50% decrease in heart tissue 
(p = 0.0172) (Fig. 3A–3C). We also observed a 30% 
decrease in S6 phosphorylation in adipose tissue, but it was 
not significant after correction for multiple comparisons 
(p = 0.5) (Fig. 3D). In contrast, tissues from mice subject 
to intermittent fasting on the 21% diet showed a significant 
increase of S6 phosphorylation in liver and adipose 
tissue, as well as a 48% increase (p = 0.058) in skeletal 
muscle (Fig. 3). Mice intermittently fasted on the 7% 
diet displayed increased S6 phosphorylation in heart and 
adipose tissue (Fig. 3). In contrast to mTORC1 activity, 
there was no effect of a PR diet on mTORC2 signaling 
as assessed by AKT S473 phosphorylation in any tissue 
(Fig. 3A–3D). However, intermittent fasting increased 
AKT S473 phosphorylation in the heart, regardless 
of diet composition, with a similar increase in AKT 
phosphorylation in 21% IF muscle and 7% IF adipose 
tissue.
DISCUSSION
Diets with chronic restriction of protein intake 
and intermittent fasting have been demonstrated to 
extend lifespan and inhibit age-related diseases such 
as cancer. Here, we compare the effect of dietary 
composition and intermittent fasting on cancer growth 
and mTOR pathway signaling. We have found that both 
a reduction in dietary protein and intermittent fasting 
slow tumor growth rate, but have distinguishable 
effects on mTOR signaling both in the tumor and the 
somatic tissues of a tumor-bearing mouse. Within the 
tumor, we determined that ad libitum feeding of a 7% 
protein diet or intermittent fasting of a 21% protein 
diet significantly inhibits mTORC1 signaling. Previous 
studies have suggested that rapamycin-resistant 
functions of mTORC1 contribute to cell growth and 
cancer progression [28], and thus it will be interesting 
to determine if reduced dietary protein intake inhibits 
both rapamycin dependent and independent functions of 
mTORC1.
Unlike reduced dietary protein intake, we found 
that intermittent feeding inhibits mTORC2 as well 
Figure 1: A low protein diet or intermittent fasting regimen slows tumor growth rate in a mouse model of breast 
cancer. A. Weights of 6 week old female mice placed on diets containing either 21% or 7% protein, which were fed either ad libitum (AL) 
or with intermittent, alternate day fasting (IF). Arrow indicates time of tumor implantation on day 29. B. Tumor volumes were measured 
weekly starting 20 days after tumor cell implantation. (n = 7–10 mice per group, a = p ≤ 0.05, b = p ≤ 0.09, 21% AL vs. all other groups; 
c = p < 0.008, 7% AL vs. 21% IF; d = p < 0.006, 7% AL vs 7% IF). Data in A-B for AL fed mice was previously published in part [7] and 
is shown here for comparison. C. Growth rates of tumors in mice on each indicated diet was calculated using the method of Laird and Ware 
[34] from tumor volumes measured 3–12 weeks after tumor implantation (n = 9–10 mice per group, p < 0.0001).
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as mTORC1. Inhibition of mTORC2 inhibits cancer 
progression in at least some cancers [29, 30], and thus 
intermittent fasting may be a particularly potent anti-
cancer therapy. It is potentially important that we 
sacrificed the intermittently fasted mice following a day 
on which they enjoyed access to food; mTOR signaling 
in intermittently fasted mice following a fasting day 
might look quite different (e.g., mTORC1 signaling 
might be significantly decreased relative to ad libitum fed 
mice). It remains to be determined if additional, mTOR-
independent mechanisms may also contribute to the anti-
cancer effects of PR and IF dietary regimens.
Within the somatic tissue of the mouse, we 
have demonstrated that a simple dietary intervention, 
reduction of dietary protein intake by 2/3rds, is sufficient 
to significantly inhibit mTORC1 signaling in the liver, 
muscle, and heart tissues of NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ mice. Importantly, this occurs in the absence of 
mTORC2 inhibition, which is responsible for many of 
the negative side effects of rapamycin on metabolism 
and immunity [16, 17, 31–33]. Protein restriction may 
therefore be a highly translatable intervention for age-
related diseases in humans, and the 2/3rds reduction in 
dietary protein we have utilized here is likely to be far 
Figure 2: A protein restricted diet inhibits mTORC1 signaling in tumors. A. Tissue lysates from tumor xenografts were 
examined for phosphorylation of S6 S240/S244 and AKT S473 by western blotting. B. Quantification of S6 and AKT phosphorylation, 
normalized to total S6 or AKT protein, was performed using NIH ImageJ. C. Quantification of S6, normalized to β-TUBULIN, was 
performed using NIH Image J (n = 7–10 tumors per group, * = p < 0.05 t-test following ANOVA).
Figure 3: A protein restricted diet inhibits mTORC1 signaling in vivo. Tissue lysates from A. liver, B. muscle, C. heart and 
D. adipose tissue were examined for phosphorylation of S6 S240/S244 and AKT S473 by western blotting. Quantification of S6 and AKT 
phosphorylation, normalized to total S6 or AKT protein, was performed using NIH ImageJ (n = 6–7 samples per group, means with the 
same letter are not significantly different from each other (Tukey–Kramer test following ANOVA, p < 0.05)).
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Table 1: Calculated composition and ingredients of experimental diets used
21% mix protein TD.10193 7% mix protein TD.10192
Diet composition
Total energy value (kcal/g) 3.6 3.6
Carbohydrate (%Kcal) 58.9 73.0
Fat (%kcal) 20.1 20.2
Protein (%Kcal) 20.9 6.8
  Leucine (g/kg) 25.4 8.8
  Isoleucine (g/kg) 7.8 2.7
  Lysine (g/kg) 16.3 4.0
  Methionine (g/kg) 6.7 1.9
  Cysteine (g/kg) 7.2 3
  Arginine (g/kg) 6.3 2.9
  Phenylalanine (g/kg) 6.6 2.4
  Tyrosine (g/kg) 6.9 2.4
  Histidine (g/kg) 3.4 1.4
  Threonine (g/kg) 9.7 3.3
  Tryptophan (g/kg) 3.4 1.0
  Valine (g/kg) 8.4 3.2
Formula (g/kg)
 Corn 430 430
 Lactalbumin (Fonterra, NZ) 177 35
 DL-Methionine 2.0 0.4
 Corn starch 149 287.4
 Maltodextrin 100 100
 Corn oil 29 32
 Olive oil 29 32
 Cellulose 30 30
 *Mineral Mix, AIN-93G-MX 35 35
 Calcium phosphate 8 8
 **Vitamin Mix, Tekland 10 10
*Mineral Mix, AIN-93G-MX (No. 94046), **Vitamin Mix, Teklad (40060)
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more sustainable than the protein-free diets used in some 
recent studies. Interestingly, while intermittent fasting 
extends mouse lifespan, here we observed increased 
mTORC1 signaling in many tissues of intermittently fasted 
mice, suggesting that the lifespan extension observed 
following IF may be mTOR-independent. Future studies 
are warranted to determine if reduced mTORC1 signaling 
is the mechanism by which PR promotes health and 
longevity, to determine how PR impacts the circulating 
and tissue levels of amino acids and their metabolites, 
and to identify how factors such as protein quality and 
genetic background may influence the effect of a PR diet 
on mTOR signaling, longevity, and age-related diseases 
including cancer.
MATERIALS AND METHODS
Antibodies to phospho-Akt S473 (4060), Akt 
(4691), phospho-S6 S240/S244 (2215) and S6 ribosomal 
protein (2217) were from Cell Signaling Technology. 
Protease and phosphatase inhibitor cocktail tablets were 
from Fisher. Other chemicals were purchased from Sigma 
unless noted. 2.0 mL Tough Tubes with Caps (13119–500) 
and 1.4 mM ceramic beads (13113–325), were purchased 
from Mo-Bio Laboratories, Carlsbad, CA.
Animals
Six week old, female NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ mice were purchased from The Jackson Laboratory. 
Mice were housed and maintained in a sterile and pathogen 
free facility, in accordance with the Institutional guidelines 
of the Institutional Animal Care and Use Committee of 
the Washington University in St. Louis. WHIM16 tumor 
cell line was generated from a patient with ER positive/
PR negative/ HER2 negative breast cancer (Washington 
University). This tumor cell line carries also a PI3K 
mutation with activation of the AKT/mTOR pathway 
(manuscript submitted). Five million WHIM16 cells 
were implanted subcutaneously under the skin. All mice 
were operated under sedation with oxygen, isoflurane and 
buprenorphine. Mice were randomly grouped and placed 
on ad libitum or alternate day fasting 21% or 7% protein 
diets prior to tumor implantation (n = 10 per group).
Feeding protocol
The two experimental diets were prepared and 
sterilized by irradiation by Harlan Laboratories (Madison, 
WI). A summary of the composition and ingredients of 
each diet are shown in Table 1. Animals were allowed 
free access to autoclaved water supply via auto-watering 
system. Female mice that were randomized into 21% 
protein diet and 7% protein diet were further randomized 
within each group to either receive food ad libitum or 
every other day.
Tumor assessment
For tumors implanted subcutaneously, tumor sizes 
and body weights were recorded once a week. Tumor sizes 
were assessed by caliper measurements of two diameters 
of the tumor (longest length × shortest length = mm2). 
Tumor growth rate was calculated by summarizing 
the means and standard deviations for each group from 
3–12 weeks following tumor cell implantation, and Laird 
and Ware’s (1982) [34] growth curve method was used 
to compare the differences between groups. All the tests 
were two-sided and a p-value of 0.05 or less was taken 
to indicate statistical significance. The statistical analysis 
was performed using SAS 9.3 (SAS Institutes, Cary, NC).
Tissue collection and immunoblotting
At the end of the xenograft experiment, at the 
conclusion of a full day during which both the ad libitum 
and intermittently fed groups had access to food, the 
food was removed at 7:30 am and the mice were then 
euthanized. The xenograft tumors were excised and 
liver, heart and skeletal muscle, and adipose tissues were 
collected, frozen immediately in liquid nitrogen and stored 
at -80C. Tissue samples were lysed in cold RIPA buffer 
supplemented with phosphatase inhibitor and protease 
inhibitor cocktail tablets. Tissues were lysed in RIPA 
buffer as previously described [18] using a FastPrep 24 
(M.P. Biomedicals) with bead-beating tubes and ceramic 
beads (Mo-Bio Laboratories), and then centrifuged for 
10 minutes at 15,000 rpm. Protein concentration was 
determined by Bradford (Bio-Rad). 20 μg protein was 
separated by sodium dodecylsulpahte-polyacrylamide gel 
electrophoresis (SDS-PAGE) on 10% resolving gels (Life 
Technologies/ThermoFisher). Imaging was performed 
using a GE ImageQuant LAS 4000 imaging station. 
Quantification was performed by densitometry using 
ImageJ software. Statistical analysis was performed by 
one-way ANOVA followed by post-hoc tests using Prism 
(GraphPad Software).
ACKNOWLEDGMENTS
We would like to thank all the members of the 
Lamming and Fontana labs, as well as the Davis, Kimple 
and Merrins labs for the use of equipment and thoughtful 
discussion.
FUNDING
The Fontana lab is supported by grants from the 
Bakewell Foundation. The Lamming lab is supported in 
part by a grant from the National Institute of Health and 
startup funds from the UW-Madison School of Medicine 
and Public Health and the UW-Madison Department 
of Medicine. D.W.L is supported in part by a K99/R00 
Oncotarget31239www.impactjournals.com/oncotarget
Pathway to Independence Award from the NIH/NIA 
(AG041765). This work was supported using facilities 
and resources from the William S. Middleton Memorial 
Veterans Hospital. This work does not represent the views 
of the Department of Veterans Affairs or the United States 
Government.
CONFLICTS OF INTEREST
None of the authors had conflicts of interest.
REFERENCES
1. Solon-Biet SM, McMahon AC, Ballard JW, Ruohonen K, 
Wu LE, Cogger VC, Warren A, Huang X, Pichaud N, 
Melvin RG, Gokarn R, Khalil M, Turner N, Cooney GJ, 
Sinclair DA, Raubenheimer D, et al. The ratio of macronu-
trients, not caloric intake, dictates cardiometabolic health, 
aging, and longevity in ad libitum-fed mice. Cell Metab. 
2014; 19:418–430.
2. Arum O, Bonkowski MS, Rocha JS, Bartke A. The growth 
hormone receptor gene-disrupted mouse fails to respond to 
an intermittent fasting diet. Aging Cell. 2009; 8:756–760.
3. Fontana L, Partridge L. Promoting health and longevity 
through diet: from model organisms to humans. Cell. 2015; 
161:106–118.
4. Mattson MP, Allison DB, Fontana L, Harvie M, 
Longo  VD, Malaisse WJ, Mosley M, Notterpek L, 
Ravussin E, Scheer FA, Seyfried TN, Varady KA, Panda S. 
Meal frequency and timing in health and disease. Proc Natl 
Acad Sci U S A. 2014; 111:16647–16653.
5. Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, 
Cheng CW, Madia F, Fontana L, Mirisola MG, Guevara-
Aguirre J, Wan J, Passarino G, Kennedy BK, Wei M, 
Cohen P, Crimmins EM, Longo VD. Low protein intake 
is associated with a major reduction in IGF-1, cancer, and 
overall mortality in the 65 and younger but not older popu-
lation. Cell Metab. 2014; 19:407–417.
6. Parrella E, Maxim T, Maialetti F, Zhang L, Wan J, Wei M, 
Cohen P, Fontana L, Longo VD. Protein restriction cycles 
reduce IGF-1 and phosphorylated Tau, and improve behav-
ioral performance in an Alzheimer’s disease mouse model. 
Aging Cell. 2013; 12:257–268.
7. Fontana L, Adelaiye RM, Rastelli AL, Miles KM, 
Ciamporcero E, Longo VD, Nguyen H, Vessella R, Pili R. 
Dietary protein restriction inhibits tumor growth in human 
xenograft models. Oncotarget. 2013; 4:2451–2461.
8. Tajes M, Gutierrez-Cuesta J, Folch J, Ortuno-Sahagun D, 
Verdaguer E, Jimenez A, Junyent F, Lau A, Camins A, 
Pallas M. Neuroprotective role of intermittent fasting in 
senescence-accelerated mice P8 (SAMP8). Exp Gerontol. 
2010; 45:702–710.
9. Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO. 
Long-term effects of calorie or protein restriction on serum 
IGF-1 and IGFBP-3 concentration in humans. Aging Cell. 
2008; 7:681–687.
10. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional 
regulation of the insulin-like growth factors. Endocr Rev. 
1994; 15:80–101.
11. Lamming DW. Diminished mTOR signaling: a com-
mon mode of action for endocrine longevity factors. 
SpringerPlus. 2014; 3:735.
12. Anisimov VN, Zabezhinski MA, Popovich IG, 
Piskunova TS, Semenchenko AV, Tyndyk ML, 
Yurova MN, Antoch MP, Blagosklonny MV. Rapamycin 
extends maximal lifespan in cancer-prone mice. Am J 
Pathol. 2010; 176:2092–2097.
13. Blagosklonny MV. Once again on rapamycin-induced insu-
lin resistance and longevity: despite of or owing to. Aging 
(Albany NY). 2012; 4:350–358.
14. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, 
Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, 
Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin 
fed late in life extends lifespan in genetically heterogeneous 
mice. Nature. 2009; 460:392–395.
15. Trelinska J, Dachowska I, Kotulska K, Fendler W, 
Jozwiak S, Mlynarski W. Complications of mammalian 
target of rapamycin inhibitor anticancer treatment among 
patients with tuberous sclerosis complex are common and 
occasionally life-threatening. Anti-cancer drugs. 2015; 
26:437–442.
16. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and 
mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 
2013; 123:980–989.
17. Lamming DW, Mihaylova MM, Katajisto P, Baar EL, 
Yilmaz OH, Hutchins A, Gultekin Y, Gaither R, 
Sabatini DM. Depletion of Rictor, an essential protein com-
ponent of mTORC2, decreases male lifespan. Aging Cell. 
2014; 13:911–917.
18. Lamming DW, Ye L, Katajisto P, Goncalves MD, 
Saitoh M, Stevens DM, Davis JG, Salmon AB, 
Richardson A, Ahima RS, Guertin DA, Sabatini DM, 
Baur JA. Rapamycin-induced insulin resistance is mediated 
by mTORC2 loss and uncoupled from longevity. Science. 
2012; 335:1638–1643.
19. Schreiber KH, Ortiz D, Academia EC, Anies AC, Liao CY, 
Kennedy BK. Rapamycin-mediated mTORC2 inhibition 
is determined by the relative expression of FK506-binding 
proteins. Aging Cell. 2015; 14:265–273.
20. Harputlugil E, Hine C, Vargas D, Robertson L, 
Manning BD, Mitchell JR. The TSC complex is required for 
the benefits of dietary protein restriction on stress resistance 
in vivo. Cell reports. 2014; 8:1160–1170.
21. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, 
Sinha S, Jordan A, Beck AH, Sabatini DM. A diverse array 
of cancer-associated MTOR mutations are hyperactivating 
and can predict rapamycin sensitivity. Cancer discovery. 
2014; 4:554–563.
Oncotarget31240www.impactjournals.com/oncotarget
22. Bar-Peled L, Chantranupong L, Cherniack AD, 
Chen WW, Ottina KA, Grabiner BC, Spear ED, Carter SL, 
Meyerson M, Sabatini DM. A Tumor suppressor com-
plex with GAP activity for the Rag GTPases that sig-
nal amino acid sufficiency to mTORC1. Science. 2013; 
340:1100–1106.
23. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, 
Glogauer M, el-Hashemite N, Onda H. A mouse model of 
TSC1 reveals sex-dependent lethality from liver hemangio-
mas, and up-regulation of p70S6 kinase activity in Tsc1 null 
cells. Hum Mol Genet. 2002; 11:525–534.
24. Bhasin KK, van Nas A, Martin LJ, Davis RC, Devaskar SU, 
Lusis AJ. Maternal low-protein diet or hypercholesterol-
emia reduces circulating essential amino acids and leads to 
intrauterine growth restriction. Diabetes. 2009; 58:559–566.
25. Chantranupong L, Wolfson RL, Sabatini DM. Nutrient-
sensing mechanisms across evolution. Cell. 2015; 
161:67–83.
26. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, 
Pearson RB. Coordinate regulation of ribosome biogen-
esis and function by the ribosomal protein S6 kinase, a 
key mediator of mTOR function. Growth Factors. 2007; 
25:209–226.
27. Thoreen CC, Chantranupong L, Keys HR, Wang T, 
Gray NS, Sabatini DM. A unifying model for mTORC1-
mediated regulation of mRNA translation. Nature. 2012; 
485:109–113.
28. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, 
Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. 
An ATP-competitive mammalian target of rapamycin 
 inhibitor reveals rapamycin-resistant functions of mTORC1. 
J Biol Chem. 2009; 284:8023–8032.
29. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, 
Sheen JH, Mullholland DJ, Magnuson MA, Wu H, 
Sabatini DM. mTOR complex 2 is required for the devel-
opment of prostate cancer induced by Pten loss in mice. 
Cancer Cell. 2009; 15:148–159.
30. Moschetta M, Reale A, Marasco C, Vacca A, Carratu MR. 
Therapeutic targeting of the mTOR-signalling pathway in 
cancer: benefits and limitations. British journal of pharma-
cology. 2014; 171:3801–3813.
31. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. 
Regulation of immune responses by mTOR. Annual review 
of immunology. 2012; 30:39–68.
32. Lamming DW, Demirkan G, Boylan JM, Mihaylova MM, 
Peng T, Ferreira J, Neretti N, Salomon A, Sabatini DM, 
Gruppuso PA. Hepatic signaling by the mechanistic tar-
get of rapamycin complex 2 (mTORC2). FASEB J. 2014; 
28:300–315.
33. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, 
Lawrence JC Jr. Muscle-specific deletion of rictor impairs 
insulin-stimulated glucose transport and enhances Basal 
glycogen synthase activity. Mol Cell Biol. 2008; 28:61–70.
34. Laird NM, Ware JH. Random-effects models for 
 longitudinal data. Biometrics. 1982; 38:963–974.
